RxDoctor Payments Data

Ricky Deerman, MD

Family Medicine · Rainsville, ALNPI 1043281975

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 89 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$340
  • Lilly USA, LLC$229
  • AstraZeneca$174
  • Pfizer$142
  • Exact Sciences$108
  • Merck$76
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$1,37599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,387 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$30,298
Medicare patients
134
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon15$335,707
EliquisApixaban136$103,164
JardianceEmpagliflozin123$91,042
FarxigaDapagliflozin Propanediol88$84,963
OzempicSemaglutide72$82,296
JanuviaSitagliptin Phosphate93$67,657
RybelsusSemaglutide39$50,803
MounjaroTirzepatide29$30,107
XareltoRivaroxaban21$28,647
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$17,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,411
TrulicityDulaglutide14$12,943
Tresiba Flextouch U-200Insulin Degludec12$12,297
EntrestoSacubitril/Valsartan18$12,183
JanumetSitagliptin Phos/Metformin Hcl11$10,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$340$133,099111 claims
PfizerEliquis$142$103,164136 claims
Boehringer IngelheimJardiance, Tradjenta$50$100,941134 claims
MerckJanuvia, Janumet, Janumet Xr$76$86,513119 claims
AstraZenecaFarxiga$174$84,96388 claims
Lilly USA, LLCMounjaro, Trulicity$229$43,05043 claims
Johnson & JohnsonXarelto$23$28,64721 claims
GSKTrelegy Ellipta$65$14,41123 claims
NovartisEntresto$36$12,18318 claims
AbbVieSynthroid$36$2,61524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Rainsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →